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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of exercise therapies on the prevention or management of aromatase inhibitor-induced musculoskeletal symptoms
(AIMSS) in women with stage I-III hormone receptor-positive breast cancer.
B A C K G R O U N D
Description of the condition
Breast cancer remains a major public health problem despite ad-
vances in screening and treatment. There was an estimated 1.67
million new cases diagnosed in 2012, making breast cancer the
most common non-skin cancer in women (Ferlay 2012). With
522,000 deaths, breast cancer was the fifth most common cause of
cancer death globally in 2012 (Ferlay 2012). In women in devel-
oped regions of the world, breast cancer is second to lung cancer
as the leading cause of cancer death, and in less developed regions,
breast cancer remains the leading cause of cancer death (Ferlay
2012). Hormone receptor-positive breast cancer, i.e. oestrogen re-
ceptor (ER)-positive, or progesterone receptor (PR)-positive, or
both, accounts for about 80% of breast cancer, with women with
early breast cancer usually having oestrogen or ’endocrine-sensi-
tive’ cancer (Nadji 2005). Treatment of postmenopausal women
with hormone receptor-positive breast cancer with aromatase in-
hibitor (AI) medications is effective. Five years of AI therapy in
early breast cancer improves disease-free survival (DFS) and breast
cancer specific survival (BCSS) when compared to another hor-
monal therapy, tamoxifen (Aydiner 2013; EBCTCG 2015).
However, AIs are commonly associated with joint and muscu-
lar symptoms, referred to as aromatase inhibitor-induced muscu-
loskeletal symptoms (AIMSS) (Lintermans 2013). Nearly half of
all women on AIs experience these side effects (Beckwee 2017).
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AIMSS often presents as symmetrical pain or soreness in multi-
ple joints, and is also often associated with early morning stiffness
(Burstein 2007). Despite the survival advantage of AIs, these side
effects are causing a quarter to half of all women on this treat-
ment to discontinue (Chim 2013; Henry 2012; Kadakia 2016).
An association between switching AIs and the development of new
musculoskeletal pain has been identified (Kemp-Casey 2017). If
AIMSS can be managed, then quality of life and adherence to
treatment may improve, and the survival advantage from using AI
therapy may not be compromised.
Description of the intervention
Exercise can be defined as “a subset of physical activity that is
planned, structured, repetitive, and has as a final or an intermedi-
ate objective of the improvement or maintenance of physical fit-
ness” (Caspersen 1985).The definition of therapy in theMerriam-
Webster dictionary is the “therapeutic treatment especially of bod-
ily, mental, or behavioral disorder” (Merriam-Webster). Exercise
therapies investigated in this review involve a variety of therapeu-
tic interventions intended to improve or maintain fitness. These
include, but are not restricted to, cardiovascular and resistance ex-
ercises, yoga, tai-chi, aquatic exercise, walking and Pilates.
How the intervention might work
The cause of AIMSS is unknown, and therefore themechanism for
the effectiveness of exercise therapies on AIMSS cannot be ascer-
tained. There has been a growing interest in conducting research
into the effect of exercise on a wide variety of conditions, such as
the effect on cancer mortality, recurrence and treatment-related
adverse effects (Cormie 2017), cancer-related fatigue and mobility
(Dennett 2016), quality of life in cancer survivors (Mishra 2012),
the immune system (Szlezak 2016), and rheumatological condi-
tions, such as osteoarthritis (Fransen 2014; Osteras 2017). There
has been a large phase III randomised control trial (RCT) inves-
tigating the intervention of cardiovascular and resistance exercise
in the treatment of AIMSS, which reported a clinically signifi-
cant benefit with the use of exercise (Irwin 2015). Therefore, even
though the mechanism of any potential benefit of exercise in this
area is largely unknown, a positive result from a large phase III
RCT, plus multiple other smaller studies in this field, warrants a
comprehensive review of these therapies.
Why it is important to do this review
AIMSS has a clinical impact on the management of women with
breast cancer, as studies have shown significant rates of subop-
timal adherence to AIs (Brier 2017; Hadji 2014; Henry 2012;
Hershman 2011; Partridge 2008; Presant 2007). Non-compliance
with endocrine therapies in the adjuvant setting may impact on
women’s survival (Hershman 2011). To date, there is limited evi-
dence regarding the best management options for AIMSS. With
a growing emphasis on the management of survivorship issues for
women with early breast cancer, this area of research is very topical,
and of increasing importance. It has been identified that oncol-
ogists may feel ill-equipped to prescribe exercise to women with
early breast cancer (Smaradottir 2017), and providing a stronger
evidence base for the role of exercise in managing symptoms may
assist with this issue.
O B J E C T I V E S
To assess the effects of exercise therapies on the prevention orman-
agement of aromatase inhibitor-induced musculoskeletal symp-
toms (AIMSS) in women with stage I-III hormone receptor-pos-
itive breast cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) looking at the prevention
or management of AIMSS in women with stage I-III hormone
receptor-positive breast cancer. AIMSSwill be defined by the study
authors of each trial. We will exclude animal and in vitro studies.
We will consider studies in all languages for inclusion.
Types of participants
Women aged ≥18 years with stage I-III oestrogen receptor (ER)-
positive, or progesterone receptor (PR)-positive breast cancer, or
both, being treated adjuvantly with aromatase inhibitors (AIs).
Types of interventions
We will include all exercise therapy interventions, such as aerobic
and resistance exercise, tai chi, yoga and aqua aerobics. We will
exclude musculoskeletal manipulation therapies, such as massage
and kinesiology. We will not impose any restriction on the type
of comparator arm; comparator arms may include an alternative
type of exercise, no exercise, or a waiting-list control.
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Types of outcome measures
Primary outcomes
• Symptoms of AIMSS (pain, stiffness, and grip-strength)
from baseline. These will preferably be assessed by validated
questionnaires, such as the Visual Analogue Scale (VAS), Brief
Pain Inventory (BPI), Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC), Functional
Assessment of Cancer Therapy - General (FACT-G), Medical
Outcome Study Short Form 36 (SF-36), and the Modified Score
for the Assessment of Chronic Rheumatoid Affections of the
Hands (M-SACRAH)
• Safety of the intervention, including adverse effects, such as
injury
Secondary outcomes
• Incidence of AIMSS
• Persistence and compliance of women continuing to take
their AI medication due to the intervention
• Participant health-related quality of life, also preferably
assessed by validated participant-reported outcome
questionnaires
• Breast cancer specific survival (BCSS)
• Overall survival (OS)
Search methods for identification of studies
Electronic searches
We will search the following databases.
• The Cochrane Breast Cancer Group’s (CBCG’s) Specialised
Register. We will extract and consider for inclusion in the review
trials with the key words “breast cancer” and related terms,
“aromatase inhibitors”, “exemestane”, “anastrozole”, “letrozole”,
“exercise”, “physical activity”, “resistance training”, “yoga”,
“walking”, “T’ai chi”.
• MEDLINE (via PubMed) from 1946 to present. (See
Appendix 1).
• Embase (via Embase.com) from 1947 to present. (See
Appendix 2).
• CENTRAL (the Cochrane Library, latest issue. (See
Appendix 3).
• The WHO International Clinical Trials Registry Platform
(ICTRP) search portal (apps.who.int/trialsearch) for all
prospectively registered and ongoing trials. (See Appendix 4).
• Clinicaltrials.gov (clinicaltrials.gov). (See Appendix 5).
• CINAHL (via EBSCO) from 1937 to present. (See
Appendix 6)
Searching other resources
Bibliographic searching
We will try to identify further studies from reference and citation
lists of identified relevant trials or reviews. We will obtain a copy
of the full article for each reference reporting a potentially eligible
trial. Where this is not possible, such as with the inclusion of
conference abstracts, we may source additional information from
clinical trial databases, and we will attempt to contact authors to
provide additional information.
Grey searching
We will screen conference abstracts from major conferences (i.e.
San Antonio Breast Cancer Symposium (SABCS) and American
Society of Clinical Oncology (ASCO)) via the Cochrane Breast
Cancer Group’s Specialised Register and Embase search results
(see Electronic searches). We will also search Google Scholar by
applying a two-year date limit.
Data collection and analysis
Selection of studies
Two review authors (KER and KR) will screen retrieved abstracts
from the literature search and assess whether the abstracts meet
the specified selection criteria. Subsequently, KER and KR will
then review full-texts of all remaining studies to ensure that they
still meet the selection criteria. Any disagreements on study selec-
tion will be resolved by a separate review author (NW). We will
record the selection process in a PRISMA flow diagram (Liberati
2009). We will document the reason for excluding any studies in
the ’Characteristics of excluded studies’ tables. We will translate
articles in languages other than English (where possible), when
relevant to this review.
Data extraction and management
We will perform data extraction using a standard data extraction
form that includes the following.
Characteristics of the study
• Study sponsors and author affiliations
• Study funding
• Methods, including study design, method of sequence
generation, allocation concealment, blinding of participants and
personnel, blinding of outcome, participant attrition and
exclusions, and selective outcome reporting
• Full-text availability versus abstract only
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Characteristics of the study population
• Country of enrolment
• Inclusion/exclusion criteria
• Study definition of AIMSS
• Number of participants in each treatment arm
• Mean and range of participant ages
• Type of AI prescribed to the participant
Characteristics of the intervention
• Description of the intervention
◦ Aerobic/resistance/combination/other
◦ Exercise intensity: mild/moderate/vigorous
◦ Frequency and duration of sessions
◦ Duration of intervention period
◦ Supervised versus home-based, group versus individual
• Details of control or waiting-list group
• Compliance with intervention
• Safety
Characteristics of the outcomes
• Scoring systems used (and documentation of participant-
reported outcomes versus investigator-reported outcomes)
• Outcomes of pain, stiffness, grip-strength and health-
related quality of life
• Change in incidence of AIMSS
• Timing of outcome data collection, including length of time
between intervention and last collected outcome measurement
• Follow-up period
Two review authors (KER and KR) will perform data extraction
and a third review author (NW) will resolve disagreements, if
needed. KER will enter data into Review Manager 5 (Review
Manager 2014). If there is more than one publication for a study,
we will extract the data from all publications as required, but we
will consider themost recent version of the study to be the primary
reference. If possible, we will combine records relating to the same
study under an overall trial name or ID.
Assessment of risk of bias in included studies
We will perform assessment of risk of bias for all RCTs using
Cochrane’s ’Risk of bias’ assessment tool (Higgins 2011). This in-
cludes the assessment of seven specific domains: random sequence
generation; allocation concealment; blinding of participants and
personnel; blinding of outcome assessment; incomplete outcome
data; selective reporting; and other sources of bias. We will assess
each trial domain as high risk, low risk or unclear risk. Two review
authors (KER and KR) will independently assess studies for risk
of bias and a third review author (NW) will resolve any disagree-
ments. Where there is incomplete reporting of the conduct of a
study, we will attempt to contact the authors of the study to clarify
any uncertainties. We will incorporate a summary table, listing the
’Risk of bias’ judgement for all studies into the review results.
Measures of treatment effect
We expect that studies will use a variety of different tools to mea-
sure the outcomes of interest (pain, stiffness, grip-strength and
health-related quality of life) and will be reporting continuous
outcomes. We therefore, plan to measure the treatment effect by
performing a standardised mean difference (SMD) analysis, using
a random-effects model to combine data from different instru-
ments measuring the same domain. If we cannot obtain standard
deviations (SDs) for studies, we will attempt to impute the stan-
dard deviation as per Chapter 16 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). By performing
a SMD analysis, we run the risk of giving greater weight to the
studies reporting change-from-baseline SDs, as the SDs in these
studies may be more precise than studies only reporting final value
SDs (Deeks 2011). Therefore, where possible, we will perform a
separate analysis on final values and change-from-baseline values,
and compare the results.
If studies report dichotomous outcomes, we will measure the treat-
ment outcome by the risk ratio (RR), in combination with a 95%
confidence interval (CI). We will report the ratio of treatment ef-
fect for the response so that a RR less than 1.0 favours the inter-
vention group for relief of AIMSS symptoms and a RR greater
than 1.0 favours the control group.
Unit of analysis issues
We will perform the analysis of studies with non-standard designs
as per the recommendations in Chapter 16 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). For
cross-over trial designs, we will take the within-person design into
account, so that we minimise the study receiving too little weight
in the meta-analysis, and therefore risk potentially disguising clin-
ically important heterogeneity. We will also adjust the analysis for
correlation, if required. For multiple-arm studies, where possible,
we will combine all intervention groups into a single intervention
group, and combine all control groups into a single control group.
We will then undertake a single pair-wise comparison, which will
overcome the unit of analysis issue of a potential correlation be-
tween the estimated intervention effect ofmultiple comparisons. If
we deem this method to be unsuitable, we will use one of the other
recommended approaches from Chapter 16.5.4 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
such as undertaking a multiple treatments meta-analysis, or to in-
clude two or more correlated comparisons, and account for the
correlation.
Dealing with missing data
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In the case of missing data, we will source additional information
through clinical trial registries or data repositories. If the required
data are still not available, we will contact original investigators via
email, or written correspondence, or both, and give three weeks
to reply to the request. If we do not obtain a reply, we will attempt
further contact with the original investigators, giving them an
additional two weeks to reply. If we are unable to obtain missing
data, we will explain this in the Discussion section of our review.
Assessment of heterogeneity
We will assess clinical heterogeneity using the I2 statistic, Chi2
test, and visual inspection of forest plots, as recommended in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). An I2 result of 30% to 60% may represent moderate het-
erogeneity, a result of 50% to 90% may represent substantial het-
erogeneity, and a result of 75% to 100% represents considerable
heterogeneity (Higgins 2011). The importance of the I2 result will
depend on themagnitude and direction of effects, and the strength
of evidence for heterogeneity. If there is significant heterogeneity,
we will use a random-effects model for analysis of results. For the
Chi2 test, P < 0.1 indicates significant heterogeneity.
Assessment of reporting biases
We will assess reporting biases by visual examination of funnel
plots for asymmetry. Testing for funnel plot asymmetry, and the
limitations involved in this assessment will be guided by Chapter
10.4 of the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011). As funnel plot asymmetry can be affected
by sample size and reporting biases (Egger 1998), we may need to
carry out additional sensitivity tests.
Data synthesis
We will perform statistical analysis using Review Manager 5 soft-
ware (Review Manager 2014). We will assess for clinical hetero-
geneity (see Assessment of heterogeneity). If there is significant
heterogeneity between studies, we will use a random-effects meta-
analysis, using the inverse variance method to combine data re-
sults.
We will report the meta-analysis mainly by forest plots and the
’Summary of findings’ table. If there is an insufficient number of
studies for us to pool for meta-analysis, or we cannot combine the
data, we will present the findings in a narrative manner.
’Summary of findings’ table
We will develop a ’Summary of findings’ table to assess the qual-
ity of evidence using the GRADE approach, as detailed in the
Cochrane Handbook for Systematic Reviews of Interventions, Chap-
ter 12.2 (Schünemann 2011). The GRADE approach assesses the
evidence using five considerations: study limitations, consistency
of effect, imprecision, indirectness and publication bias. The key
outcomes we will include in the ’Summary of findings’ table are:
• overall change in worst pain scores;
• overall change in stiffness scores;
• overall change in grip-strength;
• overall change in quality of life scores;
• overall change in the incidence of AIMSS;
• adverse effects, secondary to the intervention; and
• persistence and compliance of participants continuing to
take their AI medication due to the intervention.
We will develop the ’Summary of findings’ table using GRADE-
pro GDT software (GRADEpro GDT 2015). Two review au-
thors (KER, KR) will independently assess the evidence using the
GRADE approach and a third review author (NW) will resolve
any disputes.
Subgroup analysis and investigation of heterogeneity
Where possible, we will perform a subgroup analysis based on:
• type of exercise (i.e. aerobic/resistance/combination/other);
• supervised versus home-based; and
• intensity of treatment (i.e. mild/moderate/vigorous).
Sensitivity analysis
If there are adequate data available, we will undertake further sen-
sitivity analyses to examine the robustness of our conclusions. We
will do this by restricting the analysis to published studies, and also
by restricting the analysis to those studies with a low risk of bias.
We will assess this by summarising the risk of bias for an outcome
across multiple domains.
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A P P E N D I C E S
Appendix 1. MEDLINE
1. “exemestane”[Supplementary Concept])
2. “Aromatase Inhibitors”[Mesh])
3. “Aromatase Inhibitors“[Pharmacological Action]
4. ”letrozole“[Supplementary Concept]
5. ”Aminoglutethimide“[Mesh]
6. ”anastrozole“[Supplementary Concept]
7. ”atamestane“[Supplementary Concept]
8. ”Fadrozole“[Mesh]
9. ”formestane“[Supplementary Concept]
10.”vorozole“[Supplementary Concept]
11.aromatase inhibitor*
12.anastrozole
13.arimidex
14.exemestane
15.letrozole
16.aromasin
17.femara
18.fadrozole
19.formestane
20.rivizor
21.cytadren
22.aminoglutethimide
23. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19
OR 20 OR 21 OR 22
24. (breast* ORmammary) AND (cancer OR cancersOR cancerous OR carcinomaORmalignant* OR tumor OR tumors OR tumour
OR tumours OR adenocarcinoma*)
25. (”Breast“[Mesh] OR Breast Diseases”[Mesh]) AND “Neoplasms”[Mesh]
26.“Breast Neoplasms”[Mesh]
27. 24 OR 25 OR 26
28.“Exercise Therapy”[Mesh]
29. “Exercise Movement Techniques”[Mesh]
30. “Sports”[Mesh]
31. “Dancing”[Mesh]
32. “Exercise”[Mesh]
33. “Resistance training”[MeSH Terms]
34. dhyan*[Text Word] OR pranayam*[Text Word] OR asana [Text Word] OR bikram [Text Word] OR vinyasa [Text Word] OR
hatha [Text Word] OR ashtanga [Text Word] OR iyengar [Text Word] OR kundalini [Text Word] OR yoga OR yogi*
35. (sport OR sports* OR walk* OR swim* OR aquatic OR danc* OR running OR jogging OR aerobic* OR pilates OR qigong OR
“qi gong” OR “chi kung” OR “chi gung” OR exercis* OR gym* OR isometric* OR “tai chi” OR “t’ai chi” OR taijiquan)
36. (exercise* AND (therap* OR program* OR training*))
37. (physical OR strength* OR resistance OR isometric) AND (exercis* OR activit* OR therapy OR therapies OR therapeutic OR
program* OR training)
38. 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37
39. randomized controlled trial[Publication Type]
40. controlled clinical trial[Publication Type]
41. randomized[Title/Abstract]
42.randomised[Title/Abstract]
43.randomly[Title/Abstract]
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44. placebo[Title/Abstract]
45.trial[Title/Abstract])
46.groups[Title/Abstract]
47. 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 46
48. 23 AND 27 AND 38 AND 47
49. “Animals”[Mesh] NOT “Humans”[Mesh]
50. 48 NOT 49
Appendix 2. Embase
(((aromatase NEAR/2 inhibit* OR ’aromatase inhibitor’/exp OR anastrozole OR exemestane OR ’letrozole’ OR aminoglutethimide*
OR atamestane OR fadrozole OR formestane OR vorozole OR arimidex OR aromasin OR femara OR fadrozole OR lentaron OR
rivizor OR cytadren)
AND
(’breast cancer’/exp OR (breast OR mammary) NEAR/3 (cancer* OR carcinoma* OR malignan* OR tumo*r* OR adenocarcinoma*)
OR (’neoplasm’/exp AND (’breast’/exp OR ’breast disease’/exp)))
AND
(’sport’/exp OR ’dancing’/exp OR ’exercise’/exp OR ’walking’/exp OR ’physical activity’/exp ‘resistance training’/exp) OR (sport* OR
walk* OR swim* OR aquatic OR danc* OR running OR jogging OR aerobic* OR pilates OR exercis* OR gym* OR isometric*) OR
(sport*:ti,abORwalk*:ti,abOR swim*:ti,ab OR aquatic:ti,ab ORdanc*:ti,abOR running:ti,ab OR jogging:ti,ab OR aerobic*:ti,abOR
pilates:ti,ab OR exercis*:ti,ab OR gym*:ti,ab OR isometric*:ti,ab) OR (exercise* NEAR/3 (therap* OR program* OR training*)):ti,ab
OR ((physical OR strength OR resistance OR isometric) NEAR/3 (exercis* OR activity* OR therap* OR program* OR training)):ti,ab
OR (qigong:ti,ab OR ’qi gong’:ti,ab OR ’chi kung’:ti,ab OR ’chi gung’:ti,ab) OR (’tai chi’ OR ’t?ai chi’ OR taijiquan) OR (yoga:ti,ab
OR yogi*:ti,ab) OR (dhyan:ti,ab OR pranayam:ti,ab OR asana:ti,ab OR bikram:ti,ab OR vinyasa:ti,ab OR hatha:ti,ab OR ashtanga:
ti,ab OR iyengar:ti,ab OR kundalini:ti,ab)))
AND
random* OR factorial* OR crossover* OR cross NEXT/1 over* OR placebo* OR (doubl* AND blind*) OR (singl* AND blind*) OR
assign* OR allocat* OR volunteer* OR ’crossover procedure’/exp OR ’double blind procedure’/exp OR ’randomized controlled trial’/
exp OR ’single blind procedure’/exp
Appendix 3. CENTRAL
#1 MeSH descriptor: [Aromatase Inhibitors] explode all trees
#2 aromatase inhibit* (Word variations have been searched)
#3 anastrozole or exemestane or letrozole or aminoglutethimide* or atamestane or fadrozole or formestane or vorozole or arimidex or
aromasin or femara or fadrozole or lentaron or rivizor or cytadren (Word variations have been searched)
#4 #1 or #2 or #3
#5 MeSH descriptor: [Breast Neoplasms] explode all trees
#6 breast near cancer*
#7 breast near (tumour* or tumor*)
#8 breast near malignan*
#9 breast near (carcinoma* or adenocarcinoma*)
#10 #5 or #6 or #7 or #8 or #9
#11 (physical or strength* or resistance or isometric*)
#12 (exercise* or activit* or therap* or program* or training)
#13 #11 near #12
#14 exercise near (therap* or program* or training*)
#15 MeSH descriptor: [Exercise Therapy] explode all trees
#16 MeSH descriptor: [Exercise] explode all trees
#17 sport or sports* or walk* or swim* or aquatic or danc* or running or jogging or aerobic* or pilates or qigong or “qi gong” or “chi
kung” or “chi gung” or exercis* or gym* or isometric*
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#18 tai chi or t’ai chi or taijiquan or yoga or yogi* or dhyan or pranayam or asana or bikram or vinyasa or hatha or ashtanga or iyengar
or kundalini
#19 #13 or #14 or #15 or #16 or #17 or #18
#20 #4 and #10 and #19 [in trials]
Appendix 4. WHO ICTRP
breast cancer AND aromatase AND exercise
breast cancer AND aromatase AND yoga
breast cancer AND aromatase AND training
breast cancer AND aromatase AND physical activity
Appendix 5. ClinicalTrials.gov
breast cancer AND aromatase | exercise OR physical OR yoga OR activity OR training OR walking | Studies with Female Participants
Appendix 6. CINAHL
S1 (MH “Aromatase Inhibitors+”)
S2 TX (aromatase N3 inhibit*)
S3 TX exemestane
S4 TX letrozole
S5 TX Aminoglutethimide*
S6 TX atamestane
S7 TX fadrozole
S8 TX formestane
S9 TX vorozole
S10 TX arimidex
S11 TX aromasin
S12 TX femara
S13 TX fadrozole or TX anastrozole or TX rivizor or TX cytadren or TX lentaron
S14 TX hormon* W1 therapy*
S15 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14
S16 (MH “Breast Neoplasms+”)
S17 (MH “Breast+”)
S18 (MH “Neoplasms+”)
S19 S18 AND S19
S20 TX ((breast* OR mammary) N3 (cancer* OR carcinoma* OR adenocarcinoma* OR malignan* OR tumo#r*))
S21 S16 or S19 or S20
S22 (MH “Therapeutic Exercise+”)
S23 (MH “Exercise+”)
S24 (MH “Resistance Training”)
S25 (MH “Physical Activity”)
S26 (MH “Physical Fitness”) OR (MH “Physical Performance”) OR (MH “Sports+”)
S27 (MH “Walking+”) or (MH “Swimming”)
S28 (MH “Dance Therapy”) OR (MH “Dancing+”)
S29 (MH “Yoga+”) OR (MH “Tai Chi”)
S30 (MH “Qigong”)
S31 TX sport OR sports* OR walk* OR swim* OR aquatic OR danc* OR running OR jogging OR aerobic* OR pilates OR qigong
OR “qi gong” OR “chi kung” OR “chi gung” OR exercis* OR gym* OR isometric*
S32 TX ((physical OR strength* OR resistance or isometric*) N3 (exercis* OR activit* OR therap* OR program* OR training)) or
TX (exercise W6 therap*)
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S33 TX dhyan* OR pranayam* OR asana OR bikram OR vinyasa OR hatha OR ashtanga OR iyengar OR kundalini OR yoga OR
yogi*
S34 TX “tai chi”
S35 TX “t’ai chi” or or TX (tai ji) or TX (taijiquan)
S36 S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35
S37 (MH “Clinical Trials+”)
S38 PT Clinical trial
S39 TX clinic* n1 trial*
S40 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or
(tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S41 TX randomi* control* trial*
S42 (MH “Random Assignment”)
S43 TX random* allocat*
S44 TX placebo*
S45 (MH “Placebos”)
S46 (MH “Quantitative Studies”)
S47 TX allocat* random*
S48 S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46 or S47
S49 S15 and S21 and S36 and S48
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